Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud's phenomenon: a systematic review and meta-analysis

Arch Dermatol Res. 2024 Apr 17;316(5):122. doi: 10.1007/s00403-024-02864-x.

Authors

Amr Elrosasy^#^{1

2}, Mohamed Abo Zeid^#³, Shirin Cadri⁴, Belal M Fahmy⁵, Mohamed A Elzeftawy⁶, Fatma Mohammed⁷, Alaa Ramadan⁸

Affiliations

¹ Faculty of Medicine, Cairo University, Cairo, Egypt.
² Medical research group of Egypt (MRGE), Negida Academy, Arlington, MA, US.
³ Faculty of Medicine, Tanta University, Tanta, Egypt. [email protected].
⁴ University of medicine and pharmacy Grigore T. Popa, Ia?i, Romania.
⁵ faculty of medicine, Ain shams university, Ain shams, Egypt.
⁶ Faculty of Medicine, Tanta University, Tanta, Egypt.
⁷ Faculty of Medicine, Aswan University, Aswan, Egypt.
⁸ Faculty of Medicine, South Valley University, Qena, Egypt.

^# Contributed equally.

PMID: 38630277
DOI: 10.1007/s00403-024-02864-x

No abstract available

Keywords: Botulinum Toxin; Raynaud’s phenomena; Scleroderma; Systemic Sclerosis.

Publication types

Meta-Analysis
Systematic Review
Letter

MeSH terms

Botulinum Toxins* / therapeutic use
Humans
Raynaud Disease* / drug therapy
Skin Diseases* / complications

Substances

Botulinum Toxins